Related coverage linked through entity extraction aliases.
May 28, 2026
Spyre will present SPY001 topline results in ulcerative colitis on April 13, 2026. Six Phase 2 readouts are expected in 2026; Q1 net loss was $69 million.
Jul 27, 2026
InnoCare's TYK2 inhibitor fadeucravacitinib met primary and secondary endpoints in a Phase 3 psoriasis trial, with a favorable safety profile. InnoCare plans to seek regulatory approval.
Jul 21, 2026
A retrospective study found comparable corticosteroid-free remission with upadacitinib and risankizumab in anti-TNF-exposed Crohn’s patients. Upadacitinib showed higher endoscopic remission at week 52 but more adverse events. Both JAK and IL-23 inhibitors are shaping the growing IBD treatment market.
Jul 15, 2026
Long-term QUASAR extension data show Tremfya (guselkumab) maintained clinical and endoscopic remission in ulcerative colitis through Week 140, with 80.8% in clinical remission and no new safety signals.
Jun 06, 2026
Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
Apr 17, 2026
Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.
Apr 08, 2026
The FDA has approved icotrokinra, the first oral IL-23 therapy for moderate-to-severe plaque psoriasis. Meanwhile, real-world research shows IL-23 inhibitors produce site-specific responses in high-impact areas like scalp and nails, and combination therapy with ixekizumab and tirzepatide shows superior results for psoriasis patients with obesity.
Feb 21, 2026
Long-term data from the QUASAR extension study show TREMFYA® maintained clinical remission in over 80% of ulcerative colitis patients at Week 140, with more than half achieving endoscopic remission and no new safety concerns observed.
Feb 12, 2026
AbbVie reported stronger-than-expected Q4 revenue of $16.62 billion and EPS of $2.71, beating consensus estimates. The company advanced a toxin-based therapy in Phase 2 trials and filed suit challenging Medicare drug-price negotiations for Botox.
Dec 19, 2025
Takeda announced positive Phase 3 results for zasocitinib in adults with moderate-to-severe plaque psoriasis, meeting all 44 endpoints. The company is also conducting a Phase 3 trial in pediatric patients.
